Aeonian Pharmaceuticals, Inc. ^Company

Aeonian Pharmaceuticals, Inc. is an early stage research and development biopharmaceutical company based in the San Francisco Bay Area. The company harnesses the latest scientific breakthroughs to discover, develop and commercialize innovative therapeutics for the treatment of rare and age-related diseases. Aeonian’s research focus falls on the causes of disease initiation and progression; it develops compounds that are are novel and highly selective therapeutics that modulate the mTORC1 pathway, which is at the core of many different rare diseases.

Aeonian's proprietary platform is supported by an extensive intellectual property portfolio. Part of that portfolio has been obtained by assignment from the Buck Institute of Novato, California, the nation's first independent research facility focused solely on dissecting the connection between aging and chronic diseases.